Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sylvia M. Stull"'
Autor:
Stanley R Riddell, Ekram A Gad, Sylvain Simon, Tamer Basel Shabaneh, Andrew R Stevens, Sylvia M Stull, Kristen R Shimp, Brandon W Seaton, Carla A Jaeger-Ruckstuhl, Amanda L Koehne, Jason P Price, James M Olson, Benjamin G Hoffstrom, David Jellyman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Background The paucity of tumor-specific targets for chimeric antigen receptor (CAR) T-cell therapy of solid tumors necessitates careful preclinical evaluation of the therapeutic window for candidate antigens. Human epidermal growth factor receptor 2
Externí odkaz:
https://doaj.org/article/eef8e83670544a3da80201117fcb7911
Autor:
Carla Jaeger, Yun Lo, Elena Fulton, Olivia Waltner, Tamer B. Shabaneh, Colin E. Correnti, Oliver Newsom, Ian A. Engstrom, Sami B. Kanaan, Shruti S. Bhise, Jobelle M.C. Peralta, Raymond Ruff, Jason P. Price, Sylvia M. Stull, Andrew R. Stevens, Valentin Voillet, Vishaka Muhunthan, Fionnuala Morrish, James M. Olson, Raphaël Gottardo, Jay Sarthy, Steven Henikoff, Lucas B. Sullivan, Scott N. Furlan, Stanley R. Riddell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72ef94d2d007888398e97ff450e7c929
https://doi.org/10.2139/ssrn.4402129
https://doi.org/10.2139/ssrn.4402129
Autor:
Isabel Leung, Megan L Templeton, Yun Lo, Anusha Rajan, Sylvia M Stull, Sarah M Garrison, Alexander Isaac Salter, Kimberly S Smythe, Colin E Correnti, Shivani Srivastava, Cecilia C Yeung, Stanley R Riddell
Publikováno v:
Blood Advances.
Therapy with CD19 directed chimeric antigen receptor (CAR) T cells has transformed the treatment of advanced B-cell malignancies. However, loss of or low antigen expression can enable tumor escape and limit the duration of responses achieved with CAR
Autor:
Tamer B. Shabaneh, Howell F. Moffett, Sylvia M. Stull, Thomas Derezes, Leah J. Tait, Spencer Park, Stan R. Riddell, Marc J. Lajoie
Activation of a conditional safety switch has the potential to reverse serious toxicities arising from the administration of engineered cellular therapies, including chimeric antigen receptor (CAR) T cells. The functionally inert, non-immunogenic cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a6366f67c39476257569296d744294c
https://doi.org/10.1101/2022.08.24.505164
https://doi.org/10.1101/2022.08.24.505164
Autor:
Alec B. Wilkens, Elena C. Fulton, Margot J. Pont, Gabriel O. Cole, Isabel Leung, Sylvia M. Stull, Matthew R. Hart, Irwin D. Bernstein, Scott N. Furlan, Stanley R. Riddell
Publikováno v:
Blood. 140(21)
Adoptive transfer of T cells expressing chimeric antigen receptors (CAR-T) effectively treats refractory hematologic malignancies in a subset of patients but can be limited by poor T-cell expansion and persistence in vivo. Less differentiated T-cell
Autor:
Megha Sarvothama, Sushma Yechan-Gunja, Julia L. Szeto, Scott E. James, Sylvia M. Stull, Joshua R. Veatch, Matthew Fitzgibbon, Brenda Jesernig, Shivani Srivastava, Stanley R. Riddell, Naina Singhi
Publikováno v:
The Journal of Clinical Investigation
Therapeutic vaccines that augment T cell responses to tumor antigens have been limited by poor potency in clinical trials. In contrast, the transfer of T cells modified with foreign transgenes frequently induces potent endogenous T cell responses to